Precocious Puberty Treatment Market Size, Share

Q: How Big is the Precocious Puberty Treatment Market?

The market is valued at US$ 1,716.43 million in 2023. Read Report

Q: How is the Market’s Historical Performance?

From 2018 to 2022, the market registered a 5.5 % CAGR. Read Report

Request Methodology

Precocious Puberty Treatment Market Snapshot (2023 to 2033)

The global precocious puberty treatment market is anticipated to attain an impressive valuation of US$ 1,716.43 million in 2023 and is projected to reach US$ 3,650.66 million by 2033, trailing a CAGR of 7.8% during the forecast period.

Rising focus of key players on research to develop novel drugs and expand the indication label of currently available drugs for treatment of precocious puberty is anticipated to fuel the precocious puberty treatment market growth during the forecast period.

On the other hand, the number of children suffering from hormonal disorders is increasing due to various types of inherited factors and abnormal functioning of endocrine glands. These hormonal disorders mainly growth hormone disorder led the children to adopt early puberty symptoms which affects the height and other growth phenomenon in children.

Thus, augmenting market growth. Moreover, with the rising prevalence of overactive growth hormone, children are more likely to suffer from precocious puberty. This suggests that rising prevalence of hormonal disorders are anticipated to fuel the precocious puberty treatment market growth during the forecast period.

Data Points	Key Statistics
Expected Market Value (2023)	US$ 1,716.43 million
Anticipated Forecast Value (2033)	US$ 3,650.66 million
Projected Growth Rate (2023 to 2033)	CAGR 7.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Precocious puberty treatment management Demand Analysis vs. Forecast 2023 to 2033

The market for precocious puberty treatment was worth US$ 1,310 million in 2018, while growing at a CAGR of 5.5 % during the historical period. The market's growth is driven by an increase in the number of research and development activities. This will offer lucrative opportunities for growth in the precocious puberty treatment market during the projected period. Moreover, increasing drug approvals and launches will further drive growth of this market.

Similarly, increasing investments for the development of advanced technologies and surging number of emerging markets will further provide beneficial opportunities for precocious puberty treatment market growth during the forecast period. On the other hand, higher effectiveness of triptorelin in the suppression of gonadotropin in Central Precocious Puberty (CPP) among young boys and girls is anticipated to propel precocious puberty treatment market growth.

For example, according to data published in the Scientific World Journal, in May 2012, triptorelin 11.25 mg per 90 days efficiently suppressed the pituitary-gonadal level in children with central precocious puberty from first administration. This will create more space and opportunities for market expansion. After a comprehensive analysis of above-mentioned factors, the industry for precious puberty treatment is projected to be worth USD 3650.66 million by end of the forecast period.

Which are Some Prominent Drivers of the Precocious puberty treatment market?

Use of approved therapies will propel treatment market of precocious puberty

The use of Triptodor (triptorelin), Lupron Depot-Ped (leuprolide acetate), and Supprelin LA (histrelin acetate) in treatment of precocious puberty are anticipated to fuel growth in this market. These gonadotropin-releasing hormone (GnRH) agonists are approved therapies used in treating central precocious puberty.

These agonists are used to prolong the suppression of gonadotropin secretion when required which is expected to augment the market growth. Moreover, use of triptorelin, a GnRH agonist, effectively suppresses the pituitary-gonadal axis and pubertal development in children affected with precocious puberty that is also estimated to propel growth in the market of precocious puberty treatment during the projected period. The increasing prevalence of hormonal disorders is expected to positively influence the market growth. Also, the rising incidences of obesity will propel growth during the forecast period.

Another crucial factor driving growth rate of precocious puberty treatment market is the increasing healthcare expenditure which helps in enhancing its infrastructure. Moreover, increasing initiatives by public and private organizations to spread awareness are also expected to expand precocious puberty treatment market. High disposable income and rising demand for disease-specific treatments will also result in the expansion of precocious puberty treatment market. Similarly, increasing use of radiation or chemotherapy for treatment of cancer and sedentary lifestyle of people will drive the market in the forecast period.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

High cost of treatment and lack of skilled professionals to hold back market growth

The high cost associated with the treatment is projected to restrain market growth. The lack of skilled professionals and dearth of healthcare infrastructure in developing economies will challenge the precocious puberty treatment market during the forecast period.

Furthermore, a drop in clinical visits due to COVID-19 outbreak and dearth of awareness among people will also act as restrain and will further obstruct growth market during the forecast period.

Region-Wise Insights

What are the growth prospects in North America?

North America to dominate the market with maximum share

The demand for treatment options of precocious puberty in North America is projected to be maximum in the forecast period. This region is expected to dominate the market by reaching US$ 1,704.8 million by end of the forecast period. This region is estimated to possess 46.7% market share by end of 2033 with CAGR of 7.1% during the forecast period.

North America is expected to hold a dominant position in the global central precocious puberty market over the forecast period, due to the growing availability of drugs for the treatment of precocious puberty in this region. For example, in October 2017, Arbor Pharmaceuticals, LLC and Debiopharm International SA declared the commercial availability of Triptodur in the region for the treatment of pediatric patients aged two years and older who are diagnosed with central precocious puberty (CPP). This development will benefit the market in the long run.

The growth is also attributed to rising clinical trials and proliferation in research development activities for prevention of hormonal misbalance among the children. In this region, the United States is dominating the market because of the increasing prevalence of obesity leading to early puberty among the children.

What is the growth outlook in East Asia?

East Asian market driving growth with fastest CAGR

The market of precocious puberty treatment in East Asia is estimated to witness fastest CAGR of 7.6% during the forecast period. This region is anticipated to possess 25% market share by end of 2033. Furthermore, market in this region will be worth US$ 912.6 million by end of the projected period.

The growth is attributable to factors such as presence of vast number of companies and increasing acceptance of treatment related to early puberty. In this region, Japan is dominating the growth of East-Asia precocious puberty treatment market due to rising prevalence of precocious puberty and rising girl population in this region.

Category wise Insights

By Drug Class, which segment will possess Market Dominance?

Triptorelin will fuel growth with maximum market share

This segment is anticipated to withhold 62% market share by end of the forecast period. This segment will also witness fastest CAGR growth of 9% during the forecast period. The growth is attributed to factors such as use of triptorelin as a first line therapy in treatment of precocious puberty. A new triptorelin 11.25 mg long depot formulation is now available for the treatment of precocious puberty which is regarded as the best treatment for girl child till date. The 3-month depot triptorelin is a satisfactory alternative for the therapy of children affected with precocious puberty. The rising adoption of this alternative in treating this disease is propelling the growth of this segment. Moreover, the longer intervals between injections during the period of therapy may increase acceptability and compliance with treatment. These factors are expected to fuel growth of this segment by 2033.

By Distribution Channel, which segment is expected to dominate the Market?

Hospitals pushing growth with significant market share

The hospital segment dominated the market of precocious puberty treatment in 2022, with a market share of 48.75%. This segment is anticipated to sustain its dominance by accounting for more than 58% market share by end of the forecast period. This segment will grow with a moderate CAGR of 6.1% during the projected period.

The growth is attributed to factors such as high availability of skilled professionals in hospitals and robust and organized healthcare infrastructure. Moreover, easy access of gonadotropin-releasing hormone agonist for treating precocious puberty disorder in these facilities will propel growth of this segment during the forecast period.

Start-ups in Precocious Puberty Treatment Market

Start-ups help in understanding the growth outlook of any industry. These new companies have the potential to generate high returns which directly benefits the growth of any market. These start-ups are naturally more efficient at converting inputs into outputs with more flexibility and adaptability in nature, able to shift quickly in response to volatile market conditions. Some of the start-ups that will fuel the expansion of precocious puberty treatment market are:

Medivation is a San Francisco, United States-based company that acquires early-development stage pharmaceuticals, develop those product candidates, and then partner or sell successful programs to larger companies. Their pipeline involves enzalutamide, an androgen receptor inhibitor authorized for use in the reatment of metastatic castration-resistant prostate cancer It is being further developed for earlier stages of prostate cancer, progressive breast cancer and hepatocellular carcinoma. Similarly, Talazoparib (MDV3800), an oral drug poly-ADP ribose polymerase, or PARP, inhibitor presently is in Phase 3 clinical trial for gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes possess germline mutations). They are targeting numerous other solid tumor indications in including breast (beyond gBRCA mutations), prostate, ovarian cancers, small cell lung, and Pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, licensed from CureTech in 2014, in development for diffuse large B-cell lymphoma and other hematologic malignancies, like multiple myeloma. This start-up was granted total funding of USD 100 million.
Valera Pharmaceuticals (formerly called Hydro Med Sciences) is a Denver, United States-based start-up. This company was founded in 2000. This is a specialty pharmaceutical company focused on developing products to treat urology and endocrinology disorders. Based on its Hydron technology, it is creating a soft, compact, and flexible hydrogel-based implants which can be designed to release therapeutic agents at a controlled rate. Utilizing this technology, it has marketed product Vantas, a palliative treatment of advanced prostate cancer. It also has multiple products in clinical development including Supprelin-LA for precocious puberty. In December 2006, Indevus acquired Valera for a value of $120M. It is granted funding of USD 30.5 million until now from Psilos Group, Wheatley Partners.
Indevus Pharmaceuticals is a Malvern, United States-based specialty pharmaceutical company and engaged in the acquisition and development of drugs to treat conditions in urology and endocrinology. The approved products of this company include SanActura (R) and Sanctura XRTM for overactive bladder, Supprelin (R) LA for central precocious puberty, and Delatestryl (R) to treat male hypogonadism. Its developmental stage drugs include Valstartm for bladder cancer, Pro 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens. In January 2009, the company was acquired by

Market Competition

The precocious puberty treatment market is extremely competitive and consists of various key market players. These players are developing novel delivery systems for treating precocious puberty. This is anticipated to fuel precocious puberty treatment market. The key players in this market are: Teva Pharmaceutical Industries Ltd, AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc, Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, Sun Pharmaceutical Industries Limited, and Sanofi S.A.

Key industry players are inclined on adoption of inorganic growth strategies like acquisition, partnerships, and collaboration in order to bolster their product portfolio. This is expected to propel the global precocious puberty treatment market.

In June, 2020, Ipsen Pharma underwent strategic partnership with Debiopharm for Decapeptyl (triptorelin) for another 15 years. Decapeptyl (triptorelin) is used for treating central precocious puberty in children. This strategic merger helped the company to maintain a continuous product access to patients.
In March 2022, Accord BioPharma, the United States special division of Intas Pharmaceuticals, Ltd. declared the United States launch of CAMCEVI (leuprolide) 42mg injection emulsion for the treatment of progressive prostate cancer in adults.
In February 2022, BDR Pharmaceuticals revealed its brand ENZALUTAMIDE, an antiandrogen in 160mg with brand name BDENZA for treatment of Prostate Cancer patients.
In January 2019, Debiopharm Group informed about an agreement with Allergan to begin a transition process for Trelstar (Triptorelin pamoate) intended to lead to new licensees taking over the commercialization of Trelstar in the United States and Canada and the termination of Allergan's partnership with Debiopharm for strategic reasons.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 1,716.43 million
Market Value in 2033	US$ 3,650.66 million
Growth Rate	CAGR of 7.8% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Drug Class Distribution Channel Region
Regions Covered	North America Latin America Europe East Asia South Asia Oceania Middle East and Africa
Key Countries Profiled	United States Canada Brazil Mexico Germany United Kingdom France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC Countries South Africa Israel
Key Companies Profiled	Teva Pharmaceutical Industries Ltd AbbVie Inc. Arbor Pharmaceuticals, LLC Pfizer Inc. Tolmar Pharmaceuticals, Inc. Endo International Plc. Ipsen Pharma Debiopharm Group Sun Pharmaceutical Industries Limited Sanofi S.A
Customization	Available Upon Request

Key Segments Profiled in the Precocious Puberty Treatment Industry Survey

By Drug Class:

Leuprorelin
Histrein
Triptorelin
Nafarelin

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

By Region:

North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa

Frequently Asked Questions

How Big is the Precocious Puberty Treatment Market?

The market is valued at US$ 1,716.43 million in 2023.

How is the Market’s Historical Performance?

From 2018 to 2022, the market registered a 5.5 % CAGR.

What is the Projected Size of the Precocious Puberty Treatment Market?

By 2033, the market is likely to reach US$ 3,650.66 million.

What is the Growth Potential of the Precocious Puberty Treatment Market?

The market is estimated to record a CAGR of 7.8% from 2023 to 2033.

What is the CAGR for North America’s Market?

North America’s market is expected to register a 7.1% CAGR until 2033.

Table of Content

1. Executive Summary | Precocious Puberty Treatment Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

5.3.1. Leuprorelin

5.3.2. Histrelin

5.3.3. Triptorelin

5.3.4. Nafarelin

5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

6.3.1. Hospital Pharmacies

6.3.2. Retail Pharmacies

6.3.3. Online Pharmacies

6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. South Asia

7.3.5. East Asia

7.3.6. Oceania

7.3.7. Middle East and Africa

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. The USA

8.2.1.2. Canada

8.2.2. By Drug Class

8.2.3. By Distribution Channel

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Drug Class

8.3.3. By Distribution Channel

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Drug Class

9.2.3. By Distribution Channel

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Drug Class

9.3.3. By Distribution Channel

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United Kingdom (UK)

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Drug Class

10.2.3. By Distribution Channel

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Drug Class

10.3.3. By Distribution Channel

10.4. Key Takeaways

11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. India

11.2.1.2. Malaysia

11.2.1.3. Singapore

11.2.1.4. Thailand

11.2.1.5. Rest of South Asia

11.2.2. By Drug Class

11.2.3. By Distribution Channel

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Drug Class

11.3.3. By Distribution Channel

11.4. Key Takeaways

12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.2.1. By Country

12.2.1.1. China

12.2.1.2. Japan

12.2.1.3. South Korea

12.2.2. By Drug Class

12.2.3. By Distribution Channel

12.3. Market Attractiveness Analysis

12.3.1. By Country

12.3.2. By Drug Class

12.3.3. By Distribution Channel

12.4. Key Takeaways

13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

13.2.1. By Country

13.2.1.1. Australia

13.2.1.2. New Zealand

13.2.2. By Drug Class

13.2.3. By Distribution Channel

13.3. Market Attractiveness Analysis

13.3.1. By Country

13.3.2. By Drug Class

13.3.3. By Distribution Channel

13.4. Key Takeaways

14. MIDDLE EAST AND AFRICA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

14.2.1. By Country

14.2.1.1. GCC Countries

14.2.1.2. South Africa

14.2.1.3. Israel

14.2.1.4. Rest of MIDDLE EAST AND AFRICA

14.2.2. By Drug Class

14.2.3. By Distribution Channel

14.3. Market Attractiveness Analysis

14.3.1. By Country

14.3.2. By Drug Class

14.3.3. By Distribution Channel

14.4. Key Takeaways

15. Key Countries Market Analysis

15.1. USA

15.1.1. Pricing Analysis

15.1.2. Market Share Analysis, 2022

15.1.2.1. By Drug Class

15.1.2.2. By Distribution Channel

15.2. Canada

15.2.1. Pricing Analysis

15.2.2. Market Share Analysis, 2022

15.2.2.1. By Drug Class

15.2.2.2. By Distribution Channel

15.3. Brazil

15.3.1. Pricing Analysis

15.3.2. Market Share Analysis, 2022

15.3.2.1. By Drug Class

15.3.2.2. By Distribution Channel

15.4. Mexico

15.4.1. Pricing Analysis

15.4.2. Market Share Analysis, 2022

15.4.2.1. By Drug Class

15.4.2.2. By Distribution Channel

15.5. Germany

15.5.1. Pricing Analysis

15.5.2. Market Share Analysis, 2022

15.5.2.1. By Drug Class

15.5.2.2. By Distribution Channel

15.6. UK

15.6.1. Pricing Analysis

15.6.2. Market Share Analysis, 2022

15.6.2.1. By Drug Class

15.6.2.2. By Distribution Channel

15.7. France

15.7.1. Pricing Analysis

15.7.2. Market Share Analysis, 2022

15.7.2.1. By Drug Class

15.7.2.2. By Distribution Channel

15.8. Spain

15.8.1. Pricing Analysis

15.8.2. Market Share Analysis, 2022

15.8.2.1. By Drug Class

15.8.2.2. By Distribution Channel

15.9. Italy

15.9.1. Pricing Analysis

15.9.2. Market Share Analysis, 2022

15.9.2.1. By Drug Class

15.9.2.2. By Distribution Channel

15.10. India

15.10.1. Pricing Analysis

15.10.2. Market Share Analysis, 2022

15.10.2.1. By Drug Class

15.10.2.2. By Distribution Channel

15.11. Malaysia

15.11.1. Pricing Analysis

15.11.2. Market Share Analysis, 2022

15.11.2.1. By Drug Class

15.11.2.2. By Distribution Channel

15.12. Singapore

15.12.1. Pricing Analysis

15.12.2. Market Share Analysis, 2022

15.12.2.1. By Drug Class

15.12.2.2. By Distribution Channel

15.13. Thailand

15.13.1. Pricing Analysis

15.13.2. Market Share Analysis, 2022

15.13.2.1. By Drug Class

15.13.2.2. By Distribution Channel

15.14. China

15.14.1. Pricing Analysis

15.14.2. Market Share Analysis, 2022

15.14.2.1. By Drug Class

15.14.2.2. By Distribution Channel

15.15. Japan

15.15.1. Pricing Analysis

15.15.2. Market Share Analysis, 2022

15.15.2.1. By Drug Class

15.15.2.2. By Distribution Channel

15.16. South Korea

15.16.1. Pricing Analysis

15.16.2. Market Share Analysis, 2022

15.16.2.1. By Drug Class

15.16.2.2. By Distribution Channel

15.17. Australia

15.17.1. Pricing Analysis

15.17.2. Market Share Analysis, 2022

15.17.2.1. By Drug Class

15.17.2.2. By Distribution Channel

15.18. New Zealand

15.18.1. Pricing Analysis

15.18.2. Market Share Analysis, 2022

15.18.2.1. By Drug Class

15.18.2.2. By Distribution Channel

15.19. GCC Countries

15.19.1. Pricing Analysis

15.19.2. Market Share Analysis, 2022

15.19.2.1. By Drug Class

15.19.2.2. By Distribution Channel

15.20. South Africa

15.20.1. Pricing Analysis

15.20.2. Market Share Analysis, 2022

15.20.2.1. By Drug Class

15.20.2.2. By Distribution Channel

15.21. Israel

15.21.1. Pricing Analysis

15.21.2. Market Share Analysis, 2022

15.21.2.1. By Drug Class

15.21.2.2. By Distribution Channel

16. Market Structure Analysis

16.1. Competition Dashboard

16.2. Competition Benchmarking

16.3. Market Share Analysis of Top Players

16.3.1. By Regional

16.3.2. By Drug Class

16.3.3. By Distribution Channel

17. Competition Analysis

17.1. Competition Deep Dive

17.1.1. Teva Pharmaceutical Industries Ltd.

17.1.1.1. Overview

17.1.1.2. Product Portfolio

17.1.1.3. Profitability by Market Segments

17.1.1.4. Sales Footprint

17.1.1.5. Strategy Overview

17.1.1.5.1. Marketing Strategy

17.1.2. AbbVie Inc.

17.1.2.1. Overview

17.1.2.2. Product Portfolio

17.1.2.3. Profitability by Market Segments

17.1.2.4. Sales Footprint

17.1.2.5. Strategy Overview

17.1.2.5.1. Marketing Strategy

17.1.3. Arbor Pharmaceuticals, LLC

17.1.3.1. Overview

17.1.3.2. Product Portfolio

17.1.3.3. Profitability by Market Segments

17.1.3.4. Sales Footprint

17.1.3.5. Strategy Overview

17.1.3.5.1. Marketing Strategy

17.1.4. Pfizer Inc.

17.1.4.1. Overview

17.1.4.2. Product Portfolio

17.1.4.3. Profitability by Market Segments

17.1.4.4. Sales Footprint

17.1.4.5. Strategy Overview

17.1.4.5.1. Marketing Strategy

17.1.5. Tolmar Pharmaceuticals, Inc.

17.1.5.1. Overview

17.1.5.2. Product Portfolio

17.1.5.3. Profitability by Market Segments

17.1.5.4. Sales Footprint

17.1.5.5. Strategy Overview

17.1.5.5.1. Marketing Strategy

17.1.6. Endo International plc

17.1.6.1. Overview

17.1.6.2. Product Portfolio

17.1.6.3. Profitability by Market Segments

17.1.6.4. Sales Footprint

17.1.6.5. Strategy Overview

17.1.6.5.1. Marketing Strategy

17.1.7. Ipsen Pharma

17.1.7.1. Overview

17.1.7.2. Product Portfolio

17.1.7.3. Profitability by Market Segments

17.1.7.4. Sales Footprint

17.1.7.5. Strategy Overview

17.1.7.5.1. Marketing Strategy

17.1.8. Debiopharm Group

17.1.8.1. Overview

17.1.8.2. Product Portfolio

17.1.8.3. Profitability by Market Segments

17.1.8.4. Sales Footprint

17.1.8.5. Strategy Overview

17.1.8.5.1. Marketing Strategy

17.1.9. Sun Pharmaceutical Industries Limited

17.1.9.1. Overview

17.1.9.2. Product Portfolio

17.1.9.3. Profitability by Market Segments

17.1.9.4. Sales Footprint

17.1.9.5. Strategy Overview

17.1.9.5.1. Marketing Strategy

17.1.10. Sanofi

17.1.10.1. Overview

17.1.10.2. Product Portfolio

17.1.10.3. Profitability by Market Segments

17.1.10.4. Sales Footprint

17.1.10.5. Strategy Overview

17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 13: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 14: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 15: South Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 16: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 17: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 18: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 19: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 20: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 21: Oceania Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

Table 22: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Country, 2018 to 2033

Table 23: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033

Table 24: MIDDLE EAST AND AFRICA Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033

List of Charts

Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033

Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033

Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033

Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 58: Europe Market Attractiveness by Drug Class, 2023 to 2033

Figure 59: Europe Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 62: South Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 63: South Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 65: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 68: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 69: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 70: South Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 71: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 72: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 73: South Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 74: South Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 75: South Asia Market Attractiveness by Country, 2023 to 2033

Figure 76: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 77: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 78: East Asia Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 80: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 83: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 84: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 85: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 86: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 88: East Asia Market Attractiveness by Drug Class, 2023 to 2033

Figure 89: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 90: East Asia Market Attractiveness by Country, 2023 to 2033

Figure 91: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 92: Oceania Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 93: Oceania Market Value (US$ Million) by Country, 2023 to 2033

Figure 94: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 95: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 96: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 97: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 98: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 99: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 100: Oceania Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 101: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 102: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 103: Oceania Market Attractiveness by Drug Class, 2023 to 2033

Figure 104: Oceania Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 105: Oceania Market Attractiveness by Country, 2023 to 2033

Figure 106: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Drug Class, 2023 to 2033

Figure 107: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Distribution Channel, 2023 to 2033

Figure 108: MIDDLE EAST AND AFRICA Market Value (US$ Million) by Country, 2023 to 2033

Figure 109: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Country, 2018 to 2033

Figure 110: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 111: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 112: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033

Figure 113: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033

Figure 114: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033

Figure 115: MIDDLE EAST AND AFRICA Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033

Figure 116: MIDDLE EAST AND AFRICA Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033

Figure 117: MIDDLE EAST AND AFRICA Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033

Figure 118: MIDDLE EAST AND AFRICA Market Attractiveness by Drug Class, 2023 to 2033

Figure 119: MIDDLE EAST AND AFRICA Market Attractiveness by Distribution Channel, 2023 to 2033

Figure 120: MIDDLE EAST AND AFRICA Market Attractiveness by Country, 2023 to 2033

January 2023

REP-GB-16582

296 pages

Healthcare

Sabyasachi Ghosh

Book Now

Clients

Customize This Research

Quick Contact

Chat on Whatsapp + 44 (0) 20 3287 4268 + 44 (0) 20 8123 9659 + 1 347 918 3531 Contact By Email

- Trust FMI -

- Member of -

Greater New York Chamber of Commerce

- Awarded by -

BRONZE STEVIE® Award

20th annual IBAs

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

- Recognized by -

Precocious Puberty Treatment Market

Precocious Puberty Treatment Market By Drug Class, Distribution Channel & Region | Forecast 2023 to 2033